{
  "id": 5207967,
  "title": "Keros Therapeutics director Bienaime buys $10,270 in shares",
  "url": "https://urgent.news/2026/09/03/keros-therapeutics-director-bienaime-buys-10-270-in-shares",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-03T00:15:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/keros-therapeutics-director-bienaime-buys-10270-in-shares-93CH-4886895"
  },
  "original_language": "en",
  "account": "Keros Therapeutics director Bienaime recently increased his stake in the company by purchasing 1,000 shares on August 17, 2026. The director spent $10,270 on the transaction, which was executed in line with a pre-existing Rule 10b5-1 trading plan adopted in December 2025. After completing the purchase, Bienaime now owns a total of 19,592 shares of Keros Therapeutics common stock. With KROS shares trading close to their 52-week low of $9.69, down 45% year-to-date to $11.23, the insider's move may be considered timely. The company's financial position remains robust, with a strong current ratio of 21.96 and more cash than debt on its balance sheet; however, the company is rapidly consuming its cash reserves. Keros Therapeutics has also recently appointed Anne Prener, M.D., Ph.D., as a new board member, contributing her expertise in pharmaceuticals and innovation to the leadership team.",
  "summary": null,
  "key_points": [
    "Director Bienaime bought 1,000 Keros Therapeutics shares for $10,270 on August 17, 2026.",
    "He now owns 19,592 shares of the company after the transaction.",
    "KROS shares are near 52-week low of $9.69, down 45% YTD to $11.23."
  ],
  "editors_take": "The director's purchase signals confidence in the company's prospects despite a challenging year, and may help counter the negative market trend that has seen shares hit a 52-week low.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}